Trifluridine API market is anticipated to grow at a significant CAGR of 8.7% during the forecast period (2024-2031). The market growth is attributed to increasing demand for treatment of various tumors, including herpes simplex keratitis and colorectal cancer. Developments in treatment methods, legal frameworks, and technology improvements all have an impact on the market’s growth. According to the National Center for Biotechnology Information (NCBI), in October 2022, Colorectal cancer (CRC) was the third most common cancer in males and the second most common in females, with approximately 1.9 million new cases and 0.9 million mortalities in 2020 globally. Among the patients diagnosed with CRC, 20.0% have metastatic disease and 40.0% of those treated for localized disease eventually develop systemic recurrence.
Get Free Sample link @ https://www.omrglobal.com/request-sample/trifluridine-api-market
Idoxuridine and trifluridine share a structural similarity as fluorinated pyrimidine nucleoside. It is an active antiviral drug found in ophthalmic solutions that is primarily used to treat recurrent epithelial keratitis caused by the herpes simplex virus and primary keratoconjunctivitis. Tipiracil is a nucleoside analog in which the sugar moiety has been replaced by a modified pyrrolidine system. Trifluridine is not transformed into an inactive metabolite by Tipracil. Thymidine phosphorylase inhibition and increased trifluridine bioavailability are the mechanisms underlying this trifluridine protection.
Recent Development
- In August 2023, the US FDA approved trifluridine and tipiracil (LONSURF, Taiho Oncology, Inc.) with bevacizumab, for metastatic Colorectal Cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. The recommended LONSURF dose is 35 mg/m2 orally twice daily with food on days 1 through 5 and days 8 through 12 of each 28-day cycle.
Full report of Trifluridine API Market available @ https://www.omrglobal.com/industry-reports/trifluridine-api-market
Market Coverage
- The market number available for – 2023-2031
- Base year- 2023
- Forecast period- 2024-2031
- Segment Covered-
o By Product Type
o By Application
o By End-User
- Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
- Competitive Landscape- Merck KGaA, NATCO PHARMA LTD., Pfizer Inc., Sandoz Group AG, and Taiho Pharmaceutical Co., Ltd. among others.
Key questions addressed by the report.
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- Who is the leader in the market?
- How are players addressing challenges to sustain growth?
- Where is the investment opportunity?
Global Trifluridine API Market Report Segment
By Product Type
- Trifluridine API Powder
- Trifluridine API Solution
By Application
- Antiviral Drugs
- Oncology Drugs
- Other (Scientific Research)
By End-User
- Pharmaceutical Companies
- Contract Manufacturing Organizations (CMOs)
- Academic and Research Institutes
Reasons to Buying From us –
1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/trifluridine-api-market
Media Contact:
Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
